Meet our team, Dr. Sarah Salaschek, Yasmine Azzaoui and Daniel Hoppe, at the Pharma and Biotech Patent Litigation North America Summit, which wraps up today.

The first industry-led discussion on “Understanding the Status of the UPC and Its Implications for U.S. Life Science Companies”, provided a clear look at how the Unified Patent Court is evolving and why U.S. patent owners should be paying close attention. The panel explored emerging trends from recent UPC decisions, the advantages of streamlined pan-European enforcement, and how the UPC can strengthen a transatlantic patent strategy and our partner Daniel Hoppe as well as Marc Lauzeral (Schertenleib) and Irena Royzman (Orrick, Herrington & Sutcliffe LLP) acted as speakers in this discussion.